Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism

Ayad A. Jaffa, Derek Leroith, Charles Roberts, Philip F. Rust, Ronald K. Mayfield

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Insulin-like growth factor-I (IGF-I) infusion into rats and humans reduces renal vascular resistance and raises glomerular filtration rate (GFR) and renal plasma flow (RPF). To investigate whether kinins mediate the renal vasodilatory effects of IGF-I, we infused rats with IGF-I alone or in the presence of a B2 kinin receptor antagonist. Left kidney GFR, RPF, and kinin excretion were measured during infusion of vehicle and subsequently during 60-min infusion of IGF-I or IGF-I plus kinin antagonist. IGF-I was given as a bolus (150 μg/kg body wt), followed by infusion at a rate of 8.3 μg · kg-1 · min-1 for 60 min. The kinin antagonist was infused at a dose of 1 μg · kg-1 · min-1 for 60 min before the start of IGF-I infusion. GFR and RPF increased significantly after IGF-I infusion was begun, from baseline levels of 1.70 ± 0.12 and 6.21 ± 0.34 to 2.12 ± 0.11 and 7.91 ± 0.29 ml/min, respectively, at 20 min (P <0.001). This effect was maintained throughout 60 min of infusion. The increase in GFR and RPF was associated with a marked rise in urinary kinin excretion, from a baseline of 8.51 ± 6.7 to 24.7 ± 6.7 pg/min at 20 min and 40.3 ± 10.4 pg/min at 40 min (P <0.001). Pretreatment with the kinin receptor antagonist blocked the rise in GFR and RPF in response to IGF-I. These data suggest that the renal vasodilatory effect of IGF-I is mediated by kinins.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume266
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

kinins
Kinins
insulin-like growth factor I
Insulin-Like Growth Factor I
kidneys
Renal Plasma Flow
Kidney
glomerular filtration rate
Glomerular Filtration Rate
antagonists
excretion
receptors
rats
blood vessels
Vascular Resistance
pretreatment

Keywords

  • Kinin receptor antagonist
  • Renal kallikrein
  • Renal vasodilation

ASJC Scopus subject areas

  • Physiology
  • Agricultural and Biological Sciences(all)
  • Medicine(all)

Cite this

Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism. / Jaffa, Ayad A.; Leroith, Derek; Roberts, Charles; Rust, Philip F.; Mayfield, Ronald K.

In: American Journal of Physiology - Renal Physiology, Vol. 266, No. 1, 1994.

Research output: Contribution to journalArticle

Jaffa, Ayad A. ; Leroith, Derek ; Roberts, Charles ; Rust, Philip F. ; Mayfield, Ronald K. / Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism. In: American Journal of Physiology - Renal Physiology. 1994 ; Vol. 266, No. 1.
@article{3c785664ba384e6bb13ab276ffecd3dc,
title = "Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism",
abstract = "Insulin-like growth factor-I (IGF-I) infusion into rats and humans reduces renal vascular resistance and raises glomerular filtration rate (GFR) and renal plasma flow (RPF). To investigate whether kinins mediate the renal vasodilatory effects of IGF-I, we infused rats with IGF-I alone or in the presence of a B2 kinin receptor antagonist. Left kidney GFR, RPF, and kinin excretion were measured during infusion of vehicle and subsequently during 60-min infusion of IGF-I or IGF-I plus kinin antagonist. IGF-I was given as a bolus (150 μg/kg body wt), followed by infusion at a rate of 8.3 μg · kg-1 · min-1 for 60 min. The kinin antagonist was infused at a dose of 1 μg · kg-1 · min-1 for 60 min before the start of IGF-I infusion. GFR and RPF increased significantly after IGF-I infusion was begun, from baseline levels of 1.70 ± 0.12 and 6.21 ± 0.34 to 2.12 ± 0.11 and 7.91 ± 0.29 ml/min, respectively, at 20 min (P <0.001). This effect was maintained throughout 60 min of infusion. The increase in GFR and RPF was associated with a marked rise in urinary kinin excretion, from a baseline of 8.51 ± 6.7 to 24.7 ± 6.7 pg/min at 20 min and 40.3 ± 10.4 pg/min at 40 min (P <0.001). Pretreatment with the kinin receptor antagonist blocked the rise in GFR and RPF in response to IGF-I. These data suggest that the renal vasodilatory effect of IGF-I is mediated by kinins.",
keywords = "Kinin receptor antagonist, Renal kallikrein, Renal vasodilation",
author = "Jaffa, {Ayad A.} and Derek Leroith and Charles Roberts and Rust, {Philip F.} and Mayfield, {Ronald K.}",
year = "1994",
language = "English (US)",
volume = "266",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism

AU - Jaffa, Ayad A.

AU - Leroith, Derek

AU - Roberts, Charles

AU - Rust, Philip F.

AU - Mayfield, Ronald K.

PY - 1994

Y1 - 1994

N2 - Insulin-like growth factor-I (IGF-I) infusion into rats and humans reduces renal vascular resistance and raises glomerular filtration rate (GFR) and renal plasma flow (RPF). To investigate whether kinins mediate the renal vasodilatory effects of IGF-I, we infused rats with IGF-I alone or in the presence of a B2 kinin receptor antagonist. Left kidney GFR, RPF, and kinin excretion were measured during infusion of vehicle and subsequently during 60-min infusion of IGF-I or IGF-I plus kinin antagonist. IGF-I was given as a bolus (150 μg/kg body wt), followed by infusion at a rate of 8.3 μg · kg-1 · min-1 for 60 min. The kinin antagonist was infused at a dose of 1 μg · kg-1 · min-1 for 60 min before the start of IGF-I infusion. GFR and RPF increased significantly after IGF-I infusion was begun, from baseline levels of 1.70 ± 0.12 and 6.21 ± 0.34 to 2.12 ± 0.11 and 7.91 ± 0.29 ml/min, respectively, at 20 min (P <0.001). This effect was maintained throughout 60 min of infusion. The increase in GFR and RPF was associated with a marked rise in urinary kinin excretion, from a baseline of 8.51 ± 6.7 to 24.7 ± 6.7 pg/min at 20 min and 40.3 ± 10.4 pg/min at 40 min (P <0.001). Pretreatment with the kinin receptor antagonist blocked the rise in GFR and RPF in response to IGF-I. These data suggest that the renal vasodilatory effect of IGF-I is mediated by kinins.

AB - Insulin-like growth factor-I (IGF-I) infusion into rats and humans reduces renal vascular resistance and raises glomerular filtration rate (GFR) and renal plasma flow (RPF). To investigate whether kinins mediate the renal vasodilatory effects of IGF-I, we infused rats with IGF-I alone or in the presence of a B2 kinin receptor antagonist. Left kidney GFR, RPF, and kinin excretion were measured during infusion of vehicle and subsequently during 60-min infusion of IGF-I or IGF-I plus kinin antagonist. IGF-I was given as a bolus (150 μg/kg body wt), followed by infusion at a rate of 8.3 μg · kg-1 · min-1 for 60 min. The kinin antagonist was infused at a dose of 1 μg · kg-1 · min-1 for 60 min before the start of IGF-I infusion. GFR and RPF increased significantly after IGF-I infusion was begun, from baseline levels of 1.70 ± 0.12 and 6.21 ± 0.34 to 2.12 ± 0.11 and 7.91 ± 0.29 ml/min, respectively, at 20 min (P <0.001). This effect was maintained throughout 60 min of infusion. The increase in GFR and RPF was associated with a marked rise in urinary kinin excretion, from a baseline of 8.51 ± 6.7 to 24.7 ± 6.7 pg/min at 20 min and 40.3 ± 10.4 pg/min at 40 min (P <0.001). Pretreatment with the kinin receptor antagonist blocked the rise in GFR and RPF in response to IGF-I. These data suggest that the renal vasodilatory effect of IGF-I is mediated by kinins.

KW - Kinin receptor antagonist

KW - Renal kallikrein

KW - Renal vasodilation

UR - http://www.scopus.com/inward/record.url?scp=0027940817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027940817&partnerID=8YFLogxK

M3 - Article

C2 - 8304475

AN - SCOPUS:0027940817

VL - 266

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1

ER -